Abuabara K, Azfar RS, Shin DB et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010 Sep;163(3):586- 92.
Aggarwal S, Ghilardi N, Xie et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003 Jan
17;278(3):1910-4.
Alenius GM, Stenberg B, Stenlund H, et al. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol. 2002 Dec;29(12):2577-82.
Amatore F, Villani AP, Tauber M et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–83 Armstrong AW, Schupp C, Wu J et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003- 2011. PLoS One. 2012;7(12):e52935.
Armstrong A, Jarvis S, Boehncke WH et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2200-2207.
Bachelez H, Barker J, Burden AD et al. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022 Oct;18(10):1033-1047.
Bardazzi F, Viviani F, Merli Y, et al. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience. Expert Opin Biol Ther. 2022 Apr 13:1-6 Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther. 2019 Apr;19(4):287-292.
Benáková N. Průběh, prognóza a organizace péče. In. BENÁKOVÁ, N. a kol. 2007. Psoriáza nejen pro praxi. Praha: Triton. 190s.
83 Benhadou F, Ghislain PD, Guiot F, et al. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e837-e839.
Bhosle MJ, Kulkarni A, Feldman SR et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006 Jun 6;4:35.
Bonifati C, Capoccia R, Graceffa D et al. Effectiveness of Systemic Therapies in Patients with Obesity and Psoriasis: A Single-center Retrospective Study. Acta Dermatovenerol Croat.
2021 Jul;29(2):88-93
Bos JD, Hulsebosch HJ, Krieg SR et al. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res. 1983;275(3):181-9.
Both H, Essink-Bot ML, Busschbach J et al. Critical review of generic and dermatology- specific health-related quality of life instruments. J Invest Dermatol. 2007 Dec;127(12):2726- 39.
Bozkurt B, Torre-Amione G, Warren MS et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation.
2001;103:1044-1047
Bronsard V, Paul C, Prey S et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. JEADV 2010; 24 (Suppl 2): 17–22.
Buendia-Eisman A, Arias-Santiago S. Quality of life and questionnaires in dermatology.
Actas Dermosifiliogr. 2016;107:449-50.
Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venereol 2009; 23: 561-565.
Corrao G, Cantarutti A. Building reliable evidence from real-world data: Needs, methods, cautiousness and recommendations. Pulm Pharmacol Ther. 2018 Dec;53:61-67.
Damiani G, Bragazzi NL, Karimkhani Aksut C et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study.
Front Med (Lausanne). 2021 Dec 16;8:743180.
84 Dapavo P, Siliquini N, Mastorino L et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat.
2022 Jun;33(4):2352-2357
Del Alcázar E, López-Ferrer A, Martínez-Doménech Á et al. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2022 Feb;35(2):e15231.
Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-790.
Ellinghaus D, Ellinghaus E, Nair RP et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012; 90: 636-647
Esposito M, Saraceno R, Giunta A et al. An Italian study on psoriasis and depression.
Dermatology. 2006;212(2): 123-127
Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica.
1974;148(1):1-18
Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol.
1974 Feb;109(2):207-11
Fauny M, Moulin D, D’Amico F et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132-1138
Fleming P, Roubille C, Richer V et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29(6):1063–1070 Fougerousse AC, Ghislain PD, Reguiai Z et al. Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol. 2020; 34(10): e644- e646
Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol.
2007 Nov-Dec;25(6):606-15.
85 Gaffen SL, Jain R, Garg AV et al. The IL-23-IL-17 immune axis: from mechanisms to
therapeutic testing. Nat Rev Immunol. 2014 Sep;14(9):585-600.
Galluzzo M, Tofani L, Lombardo P et al. Use of Guselkumab for the Treatment of Moderate- to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. J Clin Med. 2020 Jul 9;9(7):2170 Ge Y, Huang M, Yao YM. Biology of Interleukin-17 and Its Pathophysiological Significance in Sepsis. Front Immunol. 2020 Jul 28;11:1558.
Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis:
results from a population-based study. Arch Dermatol. 2007 Dec;143(12):1493-9.
Gerdes S, Bräu B, Hoffmann M et al. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional,
prospective, German multicenter PERSIST trial. J Dermatol. 2021 Dec;48(12):1854-1862.
Ghislain PD, Failla V, Lambert J et al. Effectiveness and tolerability of guselkumab in patients with psoriasis: A longitudinal Belgian retrospective multicenter study. JAAD Int.
2021 Jun 1;4:15-17
Gisondi P. Does systemic treatment of psoriasis reduce the risk of comorbidities? Br J Dermatol. 2020 Apr;182(4):823-824
Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat. 2010;18(4):297-304
Gisondi P, Bellinato F, Chiricozzi A et al. The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. Vaccines (Basel). 2020 Dec 2;8(4):728
Gladman DD, Antoni C, Mease P et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii14-7
Gossec L, Baraliakos X, Kerschbaumer A et al. EULAR recommendations for the
management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-712
86 Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. J Dermatolog Treat. 2020
Nov;31(7):662-679.
Greb JE, Garber C, Gottlieb AB. Effect of Psoriatic Arthritis on Treatment Response in Patients With Moderate to Severe Psoriasis. J Drugs Dermatol. 2016 Aug 1;15(8):917-22 Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007 Nov-Dec;25(6):535- 46
Guillet C, Seeli C, Nina M et al. The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis. Int J Womens Dermatol. 2022 Apr 13;8(2):e010 Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol. 2008 Aug;159 Suppl 2:2-9
Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015 Nov;64:66-73
Hoede K. The problem of heredity of psoriasis. Hautarzt. 1957 Oct;8(10):433-8
Højgaard P, Glintborg B, Kristensen LE et al. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology (Oxford). 2016 Dec;55(12):2191-2199
Hong JR, Jeong H, Kim H et al. The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study. Sci Rep. 2021 Apr 21;11(1):8588
Hrehorów E, Salomon J, Matusiak L et al. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012 Jan;92(1):67-72.
Huang H, Cai ML, Hong XJ et al. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients. Eur J Dermatol. 2020 Oct 1;30(5):554-560 Hugo J. Léčba secukinumabem u pacienta se souběhem těžké formy psoriázy a roztroušené sklerózy. Acta Medicinae, 2019; 13; 56-58
Hugo J. Psoriáza. In: Pavelka K, Šenolt L, Šedová L, Hušáková M, Heissigerová J a kol.
Spondyloartritidy. Praha: Maxdorf, 2020, s. 234-244.
87 Hugo J, Gkalpakiotis S. Aktuální přehled dostupných preparátů biologické terapie psoriázy.
Remedia 2019; 29; 254–257
Hung YT, Lin YJ, Chiu HY et al. Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice.
Ther Adv Chronic Dis. 2021 Sep 29;12:20406223211046685
Chima M, Lebwohl M. TNF inhibitors for psoriasis. Semin Cutan Med Surg. 2018 Sep;37(3):134-142.
Chiricozzi A, Romanelli P, Volpe E et al. Scanning the Immunopathogenesis of Psoriasis. Int J Mol Sci. 2018 Jan 8;19(1):179.
Choi E, Ooi XT, Chandran NS. Hidradenitis suppurativa in pediatric patients. J Am Acad Dermatol. 2022 Jan;86(1):140-147
Iznardo H, Vilarrasa E, López-Ferrer A et al. Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol. 2021 Sep;185(3):660-662 Jung SW, Lim SH, Jeon JJ et al. Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center. Biomedicines. 2022 May 3;10(5):1058
Kaltsonoudis E, Voulgari PV, Konitsiotis S, et al. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13(1):54–58
Kamiya K, Kishimoto M, Sugai J et al. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019 Sep 5;20(18):4347.
Kędra K, Janeczko K, Michalik I et al. Sexual Dysfunction in Women and Men with Psoriasis: A Cross-Sectional Questionnaire-Based Study. Medicina (Kaunas). 2022 Oct 13;58(10):1443.
Kelly-Sell M, Gudjonsson JE. Overview of psoriasis. In: Wu JJ, Feldman SR, Lebwohl MG, editors. Therapy for Severe Psoriasis. Philadelphia: Elsevier; 2016. pp. 1-15
88 Kim TW, Shim WH, Kim JM et al. Clinical characteristics of pruritus in patients with scalp psoriasis and their relation with intraepidermal nerve fiber density. Ann Dermatol. 2014 Dec;26(6):727-32.
Kimmel GW, Lebwohl M. Psoriasis: Overview and Diagnosis. Evidence-Based Psoriasis.
2018 Jul 1:1–16.
Kleinbongard P, Schulz R, Heusch G. TNF-alpha in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev. 2011;16:49-69
Kojanova M, Cetkovska P, Strosova D et al. Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic.
Dermatol Ther (Heidelb). 2021 Apr;11(2):543-553.
Kojanova M, Hugo J, Velackova B et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real- world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022
Sep;33(6):2827-2837.
Kokolakis G, Vadstrup K, Hansen JB et al. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis. Dermatology. 2022;238(4):620-629
Kolbinger F, Huppertz C, Mir A et al. IL-17A and multiple sclerosis: signaling pathways, producing cells and target cells in the central nervous systém; Curr Drug Targets. 2016;17 (16):1882–1893
Koren J, Lambert JLW, Thomsen SF et al. Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative.
Dermatol Ther (Heidelb). 2023 Jan;13(1):245-268.
Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020 Apr;182(4):840-848
Korman NJ, Malatestinic W, Goldblum OM et al. Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient's perspective. J Dermatolog Treat. 2022 Mar;33(2):733-739
89 Korte J, Sprangers MA, Mombers FM et al. Quality of life in patients with psoriasis: a
systematic literature review. J Investig Dermatol Symp Proc. 2004 Mar;9(2):140-7.
Kridin K, Shani M, Schonmann Y et al. Psoriasis and Hidradenitis Suppurativa: A Large- scale Population-based Study. J Am Acad Dermatol. 2018 Nov 28:S0190-9622(18)32962-1 Krueger G., Koo J., Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:
280–4.
Krueger G, Ellis CN. Psoriasis--recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S94-100
Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii30-6.
Kurd SK, Troxel AB, Crits-Christoph P et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol.2010;146(8):891- 895
Lebwohl MG, Papp KA, Marangell LB et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–89.e85 Li Y, Lu JJ, Zhong XY et al. Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque
Psoriasis in China: A 52-Week Single-Center Retrospective Study. Clin Cosmet Investig Dermatol. 2022 Oct 20;15:2245-2252
LoCasale RJ, Pashos CL, Gutierrez B et al. Bridging the Gap Between RCTs and RWE Through Endpoint Selection. Ther Innov Regul Sci. 2021 Jan;55(1):90-96.
Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis.
Clin Cosmet Investig Dermatol. 2014 Sep 15;7:251-9.
Lytvyn Y, Zaaroura H, Mufti A et al. Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study. JAAD Int. 2021 Jul 8;4:49-51
90 Malara G, Trifirò C, Bartolotta A et al. Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):406-412
Malatestinic W, Nordstrom B, Wu JJ et al. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials. J Manag Care Spec Pharm. 2017 Mar;23(3):370-381.
Mälkönen T, Nuutinen P, Hallinen T et al. Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis. Acta Derm Venereol.
2022 Jan 18;102:adv00631
Mason KJ, Barker JNWN, Smith CH et al. Comparison of Drug Discontinuation,
Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
JAMA Dermatol. 2018 May 1;154(5):581-588.
Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol.2020 Feb;34(2):293- 300.
Mastorino L, Susca S, Megna M et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022 May;35(5):e15378
Megna M, Potestio L, Fabbrocini G et al. Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study. Psoriasis (Auckl).
2022 Jul 14;12:205-212
Meier M, Sheth PB. Clinical spectrum and severity of psoriasis. Curr Probl Dermatol.
2009;38:1-20.
Mudigonda P, Mudigonda T, Feneran AN et al. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J. 2012 Oct 15;18(10):1.
Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol.
2007 Nov-Dec;25(6):524-8.
91 Nair RP, Henseler T, Jenisch S et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997;6:1349-56
Nishioka K, Makimura T, Ishiguro A et al. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan. Clin Pharmacol Ther. 2022 Jan;111(1):35-43.
Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci. 2020 Jul;99(1):2-8
Oguz Topal I, Baysak S, Altunay İK et al. Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a
retrospective multicenter study. An Bras Dermatol. 2022 Sep-Oct;97(5):566-574 Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J et al. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J Am Acad Dermatol. 2019 Aug;81(2):427-432
Oyinlola JO, Campbell J, Kousoulis AA. Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res. 2016 Jul 26;16:299.
Parisi R, Symmons DP, Griffiths CE et al. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377-85 Patel RV, Shelling ML, Prodanovich S et al. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011 Sep;26(9):1036-49 Patsalos O, Dalton B, Leppanen J et al. Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020 Apr 15;11:481.
Paul C, van de Kerkhof P, Puig L et al. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. Eur J Dermatol. 2012 Nov-Dec;22(6):762-9
92 Peláez Bejarano A, Robustillo Cortés MA, Villar et al. Guselkumab in moderate-to-severe plaque psoriasis: Effectiveness in real clinical practice. Rev chil dermatol 2020; 36 (3): 93-97.
Pettey AA, Balkrishnan R, Rapp SR et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003 Aug;49(2):271-5.
Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol. 2006 Mar;54(3):420-6.
Pirro F, Caldarola G, Chiricozzi A et al. Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study. Clin Drug Investig.
2021 Oct;41(10):917-925
Qureshi AA, Choi HK, Setty AR et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379‒382
Ran D, Cai M, Zhang X. Genetics of psoriasis: a basis for precision medicine. Precis Clin Med. 2019 Jun 24;2(2):120-130
Rob F, Hugo J, Saláková M et al. Prevalence of genital and oral human papillomavirus infection among psoriasis patients on biologic therapy. Dermatol Ther. 2022
Oct;35(10):e15735
Rompoti N, Katsimbri P, Kokkalis G et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study. Dermatol Ther. 2019 Sep;32(5):e13006
Roubille C, Richer V, Starnino T et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta- analysis. Ann Rheum Dis 2015; 74:480–9
Ruggiero A, Fabbrocini G, Cinelli E et al. Guselkumab and risankizumab for psoriasis: a 44- week indirect real-life comparison. J Am Acad Dermatol. 2021 Oct;85(4):1028-1030
93 Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC et al. Guselkumab: Mid- term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021 Mar;34(2):e14798
Sambandan G, Turcu-Stiolica A. Clinical Trials. In: Thomas D, editor. Clinical pharmacy education, practice and research. Amsterdam, Netherlands: Elsevier; 2019. pp. 323-44.
Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535
Scarpa R, Ayala F, Caporaso N et al. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol. 2006 Feb;33(2):210-2.
Shi LQ, Lian N, Sun JT et al. Association between the systemic treatment of psoriasis and cardiovascular risk. Chin Med J (Engl). 2021 Feb 17;134(5):518-520
Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194-9.
Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis.
Dermatology. 2007;215:17-27.
Silfvast-Kaiser AS, Homan KB, Mansouri B. A narrative review of psoriasis and multiple sclerosis: links and risks. Psoriasis (Auckl). 2019 Aug 22;9:81-90
Singh JA, Guyatt G, Ogdie A et al. Special Article: 2018 American College of
Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32
Singh S, Facciorusso A, Singh AG et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018 May 17;13(5):e0195123
Singh S, Kalb RE, de Jong EMGJ et al. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Am J Clin Dermatol. 2018 Dec;19(6):879-886
94 Slonková V., Urbánková Š., Vašků V. Hodnocení kvality života v dermatologii. Postgraduální medicína 2012; 8.
Takeshita J, Wang S, Shin DB et al. Effect of psoriasis severity on hypertension control: a population‑based study in the United Kingdom. JAMA Dermatol 2015; 151: 161‒169 Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis:
development of new criteria from a large international study. Arthritis Rheumatol 2006;
54(8): 2665–2673.
Tonel G, Conrad C, Laggner U etal. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol. 2010 Nov 15;185(10):5688-91.
Torres T, Puig L. Treatment goals for psoriasis: Should PASI 90 become the standard of care?
Actas Dermosifiliogr. 2015 Apr;106(3):155-7
Torres T, Puig L, Vender R et al. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. Am J Clin Dermatol. 2021;22:567-579
Van Geel MJ, Maatkamp M, Oostveen AM et al. Comparison of the Dermatology Life Quality Index and the Children's Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16-17 years. Br J Dermatol. 2016 Jan;174(1):152-7 Van Muijen ME, Thomas SE, Vellinga D et al. Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis. Acta Derm Venereol. 2022 Aug
11;102:adv00755
Vardy D, Besser A, Amir M et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol. 2002
Oct;147(4):736-42.
Wade R, Sharif-Hurst S, Dias S. Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups. Syst Rev.
2020;9:132
Wojciechowska-Zdrojowy M, Reid A, Szepietowski JC et al. Analysis of Sexual Problems in Men With Psoriasis. J Sex Marital Ther. 2018;44(8):737-745.